OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease
February 28, 2023 02:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye...
GreenLight Biosciences receives approval to initiate Phase I/II clinical trial of Covid-19 mRNA vaccine candidate
February 01, 2023 07:20 ET
|
GreenLight Biosciences
The Rwanda FDA has given regulatory approval to GreenLight to start a Phase I/II clinical trial of its Covid-19 vaccine candidate in Rwanda. This phase I/II clinical trial is the first step in...
Zantac Update: First Trial Set for Feb. 13, 2023
June 24, 2022 17:01 ET
|
Baum Hedlund Aristei & Goldman
Oakland, California, June 24, 2022 (GLOBE NEWSWIRE) -- The California State Court Judge overseeing the Ranitidine Products Cases JCCP NO. 5150 issued a pretrial order this week establishing a trial...
AXIM Biotech Announces New Milestones in Preparation of Dry Eye Disease Diagnostics Launch
February 15, 2022 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
AXIM is driven to positively transform the state of Dry Eye Disease (DED) testing and diagnosis The company will deploy industry leader IUL’s state-of-the-art iPeak readers Company Adds Veteran Lab...
ImCheck Announces First Patients Dosed in Phase II of EVICTION Trial for ICT01
February 03, 2022 05:03 ET
|
ImCheck Therapeutics SAS
ImCheck Announces First Patients Dosedin Phase II of EVICTION Trial for ICT01 EVICTION trial proceeds to Phase IIa based on promising Phase I patient datafor ICT01 across a broad range of...
Bispecific Antibodies Cancer Immunotherapy Clinical Trials Insight 2028
December 09, 2021 07:07 ET
|
KuicK Research
Delhi, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028 Report Analysis and Data Highlights: Research...
Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of 3Q21
June 22, 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
Phase 2 US clinical trial of Abivertinib randomized last patient (#96) on 4/07/2021.Phase 2 Brazilian clinical trial of Abivertinib randomized last patient (#400) on 06/20/2021.Studies are...
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting 2021
March 11, 2021 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting...
Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
February 26, 2021 08:23 ET
|
Novavax, Inc.
Agreement includes COVID-19 vaccine technology transfer to Takeda for local manufacturing and commercialization in JapanTakeda doses first participant in immunogenicity and safety study to support...
Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
February 16, 2021 07:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...